{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:10:44Z","timestamp":1783717844075,"version":"3.55.0"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-005318"],"award-info":[{"award-number":["INV-005318"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Progress toward measles and rubella (MR) elimination has stagnated as countries are unable to reach the required 95% vaccine coverage. Microarray patches (MAPs) are anticipated to offer significant programmatic advantages to needle and syringe (N\/S) presentation and increase MR vaccination coverage. A demand forecast analysis of the programmatic doses required (PDR) could accelerate MR-MAP development by informing the size and return of the investment required to manufacture MAPs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Unconstrained global MR-MAP demand for 2030\u20132040 was estimated for three scenarios, for groups of countries with similar characteristics (archetypes), and four types of uses of MR-MAPs (use cases). The base scenario 1 assumed that MR-MAPs would replace a share of MR doses delivered by N\/S, and that MAPs can reach a proportion of previously unimmunised populations. Scenario 2 assumed that MR-MAPs would be piloted in selected countries in each region of the World Health Organization (WHO); and scenario 3 explored introduction of MR-MAPs earlier in countries with the lowest measles vaccine coverage and highest MR disease burden. We conducted sensitivity analyses to measure the impact of data uncertainty.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For the base scenario (1), the estimated global PDR for MR-MAPs was forecasted at 30 million doses in 2030 and increased to 220 million doses by 2040. Compared to scenario 1, scenario 2 resulted in an overall decrease in PDR of 18%, and scenario 3 resulted in a 21% increase in PDR between 2030 and 2040. Sensitivity analyses revealed that assumptions around the anticipated reach or coverage of MR-MAPs, particularly in the hard-to-reach and MOV populations, and the market penetration of MR-MAPs significantly impacted the estimated PDR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Significant demand is expected for MR-MAPs between 2030 and 2040, however, efforts are required to address remaining data quality, uncertainties and gaps that underpin the assumptions in this analysis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.1037157","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T05:08:48Z","timestamp":1673845728000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Estimating the future global dose demand for measles\u2013rubella microarray patches"],"prefix":"10.3389","volume":"10","author":[{"given":"Melissa","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Malvolti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Mantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Biellik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Jarrahian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Menozzi-Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Amorij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Papania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin I.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balcha Girma","family":"Masresha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Pastor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Durrheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Giersing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Hasso-Agopsowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"key":"B1","volume-title":"Rubella: Fact Sheet","year":"2018"},{"key":"B2","volume-title":"Measles Fact Sheet","year":"2005"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.15585\/mmwr.mm7045a1","article-title":"Progress toward regional measles elimination: worldwide, 2000\u20132020","volume":"70","author":"Dixon","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B4","first-page":"205","article-title":"Measles vaccines: WHO position paper","volume":"92","year":"2017","journal-title":"Wkly Epidemiol Rec."},{"key":"B5","volume-title":"WHO\/UNICEF Coverage Estimates for 1980\u20132020","year":"2021"},{"key":"B6","first-page":"2021","volume-title":"Measles and Rubella Strategic Framework","year":"2020"},{"key":"B7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41591-021-01237-5","article-title":"A dangerous measles future looms beyond the COVID-19 pandemic","volume":"27","author":"Durrheim","year":"2021","journal-title":"Nat Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/j.vaccine.2022.03.033","article-title":"Decreasing routine vaccination rates in children in the COVID-19 era","volume":"40","author":"Maltezou","year":"2022","journal-title":"Vaccine."},{"key":"B9","volume-title":"Measles\u2013Rubella Microarray Patch (MR-MAP) Target Product Profile","year":"2019"},{"key":"B10","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.vaccine.2015.12.002","article-title":"Microneedle technology for immunisation: perception, acceptability and suitability for paediatric use","volume":"34","author":"Marshall","year":"2016","journal-title":"Vaccine."},{"key":"B11","doi-asserted-by":"publisher","first-page":"6676","DOI":"10.1016\/j.vaccine.2017.10.021","article-title":"Safety, acceptability and tolerability of uncoated and excipient-coated high density silicon micro-projection array patches in human subjects","volume":"35","author":"Griffin","year":"2017","journal-title":"Vaccine."},{"key":"B12","doi-asserted-by":"publisher","first-page":"809675","DOI":"10.3389\/fpubh.2022.809675","article-title":"Accelerating the development of measles and rubella microarray patches to eliminate measles and rubella: recent progress, remaining challenges","volume":"10","author":"Hasso-Agopsowicz","year":"2022","journal-title":"Front Public Health."},{"key":"B13","volume-title":"Global Market Study, Measles-Containing Vaccines","year":"2020"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.1037157\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T05:08:59Z","timestamp":1673845739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.1037157\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":13,"alternative-id":["10.3389\/fpubh.2022.1037157"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.1037157","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]},"article-number":"1037157"}}